These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 15729422)
21. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Feringa HH; Karagiannis SE; Chonchol M; Vidakovic R; Noordzij PG; Elhendy A; van Domburg RT; Welten G; Schouten O; Bax JJ; Berl T; Poldermans D J Am Soc Nephrol; 2007 Jun; 18(6):1872-9. PubMed ID: 17475817 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. Omland T; Sabatine MS; Jablonski KA; Rice MM; Hsia J; Wergeland R; Landaas S; Rouleau JL; Domanski MJ; Hall C; Pfeffer MA; Braunwald E; J Am Coll Cardiol; 2007 Jul; 50(3):205-14. PubMed ID: 17631211 [TBL] [Abstract][Full Text] [Related]
23. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Mukherjee D; Eagle KA; Kline-Rogers E; Feldman LJ; Juliard JM; Agnelli G; Budaj A; Avezum A; Allegrone J; FitzGerald G; Steg PG; Am J Cardiol; 2007 Jul; 100(1):1-6. PubMed ID: 17599431 [TBL] [Abstract][Full Text] [Related]
24. Angiotensin receptor blockers: novel role in high-risk patients. Javed U; Deedwania PC Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228 [TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Brugts JJ; Danser AH; de Maat MP; den Uil CA; Boersma E; Ferrari R; Simoons ML Curr Opin Cardiol; 2008 Jul; 23(4):296-301. PubMed ID: 18520711 [TBL] [Abstract][Full Text] [Related]
26. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836 [TBL] [Abstract][Full Text] [Related]
29. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685 [TBL] [Abstract][Full Text] [Related]
30. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. Schelleman H; Klungel OH; Witteman JC; Breteler MM; Hofman A; van Duijn CM; de Boer A; Stricker BH Pharmacogenomics J; 2008 Dec; 8(6):400-7. PubMed ID: 18347611 [TBL] [Abstract][Full Text] [Related]
31. Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation. Rockx MA; Haddad H Curr Opin Cardiol; 2007 Mar; 22(2):128-32. PubMed ID: 17284992 [TBL] [Abstract][Full Text] [Related]
33. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials. Saha SA; Molnar J; Arora RR Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949 [TBL] [Abstract][Full Text] [Related]
34. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI]. Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514 [TBL] [Abstract][Full Text] [Related]
35. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. Welten GM; Schouten O; Hoeks SE; Chonchol M; Vidakovic R; van Domburg RT; Bax JJ; van Sambeek MR; Poldermans D J Am Coll Cardiol; 2008 Apr; 51(16):1588-96. PubMed ID: 18420103 [TBL] [Abstract][Full Text] [Related]
36. Secondary prevention of arterial disease in very elderly people: results from a prospective registry (FRENA). López-Jiménez L; Camafort M; Tiberio G; Carmona JA; Guijarro C; Martínez-Peñalver F; Monreal M; Angiology; 2008; 59(4):427-34. PubMed ID: 18388061 [TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. Vijan SG J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392 [TBL] [Abstract][Full Text] [Related]
38. Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient. Lazar HL Ann Thorac Surg; 2005 Mar; 79(3):1081-9. PubMed ID: 15734453 [TBL] [Abstract][Full Text] [Related]
39. Lower extremity peripheral arterial disease in individuals with coronary artery disease: prognostic importance, care gaps, and impact of therapy. Makowsky MJ; McAlister FA; Galbraith PD; Southern DA; Ghali WA; Knudtson ML; Tsuyuki RT; Am Heart J; 2008 Feb; 155(2):348-55. PubMed ID: 18215607 [TBL] [Abstract][Full Text] [Related]
40. Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease. van Gilst WH; Warnica JW; Baillot R; Johnstone D; Calciu CD; Block P; Myers MG; Chocron S; Rouleau JL; Am Heart J; 2006 Jun; 151(6):1240-6. PubMed ID: 16781228 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]